Delivery Order SPE2DR25D6028-SPE2DR26FARCR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Rhophylac 300 mcg/2 mL syringes with a ceiling value of $1,720.80 and a firm fixed price structure. The contract is not set-aside and represents a competitive award to the pharmaceutical distributor. Performance will be completed by October 10, 2025, with fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,868 to AmerisourceBergen Drug Corp for the supply of Rhophylac 300 mcg/2 mL syringes. The contract is a firm fixed-price delivery order with an ultimate completion date of October 17, 2025, and represents a competitive award with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary operations as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,147.20 to AmerisourceBergen Drug Corp for Rhophylac 300 mcg/2 mL syringes on August 29, 2025, with an ultimate completion date of September 22, 2025. This firm fixed price, non-set-aside contract represents a straightforward pharmaceutical procurement executed through AmerisourceBergen's existing indefinite delivery vehicle with DLA. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a $3,824.00 delivery order by the Defense Logistics Agency on September 11, 2025, for the supply of Rhophylac 300 micrograms per 2 milliliter syringes. This is a competitively awarded, non-set-aside contract utilizing firm fixed pricing, with an ultimate completion date of October 2, 2025. The award represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with...
- The Defense Logistics Agency awarded a $2,294.40 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Rhophylac 300 mcg/2 mL syringes. This contract represents a firm fixed-price delivery order with an ultimate completion date of October 6, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was competitively awarded without set-aside designation, reflecting AmerisourceBergen's continued capability to fulfill federal...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The $2,295.05 fixed-price contract is for the delivery of RHOPHYLAC 300 MCG/2 ML SYRINGE 2ML, a specialty pharmaceutical product, with a completion date of February 21, 2024. Amerisourcebergen Drug Corp holds a larger indefinite delivery contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Rhophylac 300 mcg/2 mL syringes, with a ceiling value of $10,755.00. The contract, awarded on July 25, 2025, carries a firm fixed price structure with an ultimate completion date of August 15, 2025. This delivery order does not utilize a set-aside designation and represents a competitive award to the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of RHOGAM Ultra-Filtered Plus syringes, with a ceiling value of $3,414.75. This firm fixed-price delivery order, issued on June 24, 2025, with an ultimate completion date of July 16, 2025, represents a non-competitive award to the prime contractor. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $2,954.04 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 30, 2025, for Rhogam Ultra-Filtered Plus syringes, with an ultimate completion date of July 22, 2025. This non-set-aside contract is being performed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and holds an...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,969.36 to AmerisourceBergen Drug Corp for RhoGAM Ultra-Filtered Plus syringes. This firm fixed-price contract, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DR25D6028Indefinite Delivery Contract
- SPE2DR25D6028-SPE2DR26FARCRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RHOPHYLAC 150MCG/ML 2S, a pharmaceutical product, valued at $1,388.40 under a firm fixed-price contract. The award was made on October 30, 2025, with an ultimate completion date of October 31, 2025. This non-set-aside delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's extensive portfolio of federal contracts demonstrates its capability to supply a comprehensive range of pharmaceutical products, vaccines, and medical devices across multiple therapeutic domains. This specific delivery order for RHOPHYLAC, an immunological product, reflects the company's ongoing role as a prime vendor supporting Department of Defense healthcare requirements through its competitively awarded global pharmaceutical support vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 10/30/25 |